Recursion Pharmaceuticals Net Worth
Recursion Pharmaceuticals Net Worth Breakdown | RXRX |
Recursion Pharmaceuticals Net Worth Analysis
Recursion Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Recursion Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Recursion Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Recursion Pharmaceuticals' net worth analysis. One common approach is to calculate Recursion Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Recursion Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Recursion Pharmaceuticals' net worth. This approach calculates the present value of Recursion Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Recursion Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Recursion Pharmaceuticals' net worth. This involves comparing Recursion Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Recursion Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Recursion Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Recursion Pharmaceuticals' net worth research are outlined below:
| Recursion Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 58.84 M. Net Loss for the year was (463.66 M) with loss before overhead, payroll, taxes, and interest of (372.61 M). | |
| Recursion Pharmaceuticals currently holds about 515.44 M in cash with (359.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98. | |
| Recursion Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors |
Recursion Pharmaceuticals Quarterly Good Will |
|
Recursion Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Recursion Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Recursion Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Recursion Pharmaceuticals Target Price Consensus
Recursion target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Recursion Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Buy |
Most Recursion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Recursion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Recursion Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRecursion Pharmaceuticals Target Price Projection
Recursion Pharmaceuticals' current and average target prices are 5.84 and 7.43, respectively. The current price of Recursion Pharmaceuticals is the price at which Recursion Pharmaceuticals is currently trading. On the other hand, Recursion Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Recursion Pharmaceuticals Market Quote on 20th of July 2025
Target Price
Analyst Consensus On Recursion Pharmaceuticals Target Price
Know Recursion Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Recursion Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Recursion Pharmaceuticals backward and forwards among themselves. Recursion Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Recursion Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nvidia Corp | 2025-03-31 | 7.7 M | Fmr Inc | 2025-03-31 | 6.8 M | Geode Capital Management, Llc | 2025-03-31 | 6.4 M | Ubs Asset Mgmt Americas Inc | 2025-03-31 | 6.4 M | Data Collective Iv Gp, Llc | 2025-03-31 | 5.9 M | Ubs Group Ag | 2025-03-31 | 5.6 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 5 M | Dcvc Opportunity Fund Ii Gp, Llc | 2025-03-31 | 4 M | Exor Investments (uk) Llp | 2025-03-31 | 3.7 M | Ark Investment Management Llc | 2025-03-31 | 34.8 M | Vanguard Group Inc | 2025-03-31 | 32.3 M |
Follow Recursion Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.53 B.Market Cap |
|
Project Recursion Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.45) | (0.43) |
When accessing Recursion Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Recursion Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Recursion Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Recursion Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Recursion Pharmaceuticals. Check Recursion Pharmaceuticals' Beneish M Score to see the likelihood of Recursion Pharmaceuticals' management manipulating its earnings.
Evaluate Recursion Pharmaceuticals' management efficiency
Recursion Pharmaceuticals has return on total asset (ROA) of (0.3851) % which means that it has lost $0.3851 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.861) %, meaning that it created substantial loss on money invested by shareholders. Recursion Pharmaceuticals' management efficiency ratios could be used to measure how well Recursion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to drop to -0.4 in 2025. At this time, Recursion Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 584.1 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.77 | 3.96 | |
| Tangible Book Value Per Share | 2.01 | 1.03 | |
| Enterprise Value Over EBITDA | (3.21) | (3.37) | |
| Price Book Value Ratio | 1.79 | 1.88 | |
| Enterprise Value Multiple | (3.21) | (3.37) | |
| Price Fair Value | 1.79 | 1.88 | |
| Enterprise Value | 1.4 B | 1.8 B |
The strategic initiatives led by Recursion Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 31.0245 | Revenue | Quarterly Revenue Growth 0.069 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Recursion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Recursion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Recursion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Recursion Pharmaceuticals Corporate Filings
| 8th of July 2025 Other Reports | ViewVerify | |
F4 | 3rd of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 28th of April 2025 Other Reports | ViewVerify |
Recursion Pharmaceuticals Earnings Estimation Breakdown
The calculation of Recursion Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Recursion Pharmaceuticals is estimated to be -0.3642 with the future projection ranging from a low of -0.4102 to a high of -0.3075. Please be aware that this consensus of annual earnings estimates for Recursion Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.41 Lowest | Expected EPS | -0.31 Highest |
Recursion Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Recursion Pharmaceuticals' value are higher than the current market price of the Recursion Pharmaceuticals stock. In this case, investors may conclude that Recursion Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Recursion Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 8 | 87.34% | 0.0 | -0.3642 | -1.8 |
Recursion Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Recursion Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Recursion Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Recursion Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Recursion Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Recursion Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Recursion Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Recursion Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Recursion Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-07 | 2025-03-31 | -0.516 | -0.5 | 0.016 | 3 | ||
2025-02-25 | 2024-12-31 | -0.4168 | -0.53 | -0.1132 | 27 | ||
2024-11-06 | 2024-09-30 | -0.35 | -0.34 | 0.01 | 2 | ||
2024-08-08 | 2024-06-30 | -0.4 | -0.4 | 0.0 | 0 | ||
2024-05-09 | 2024-03-31 | -0.42 | -0.39 | 0.03 | 7 | ||
2024-02-27 | 2023-12-31 | -0.45 | -0.42 | 0.03 | 6 | ||
2023-11-09 | 2023-09-30 | -0.38 | -0.43 | -0.05 | 13 | ||
2023-08-08 | 2023-06-30 | -0.37 | -0.38 | -0.01 | 2 | ||
2023-05-08 | 2023-03-31 | -0.35 | -0.34 | 0.01 | 2 | ||
2023-02-27 | 2022-12-31 | -0.29 | -0.31 | -0.02 | 6 | ||
2022-11-08 | 2022-09-30 | -0.38 | -0.35 | 0.03 | 7 | ||
2022-08-09 | 2022-06-30 | -0.37 | -0.38 | -0.01 | 2 | ||
2022-05-10 | 2022-03-31 | 0.1 | -0.33 | -0.43 | 430 | ||
2022-03-23 | 2021-12-31 | -0.31 | -0.38 | -0.07 | 22 | ||
2021-11-10 | 2021-09-30 | -0.28 | -0.28 | 0.0 | 0 | ||
2021-08-13 | 2021-06-30 | -0.23 | -0.31 | -0.08 | 34 | ||
2021-05-12 | 2021-03-31 | -0.2367 | -1.33 | -1.0933 | 461 | ||
2021-03-03 | 2020-12-31 | 0 | -0.25 | -0.25 | 0 |
Recursion Pharmaceuticals Corporate Management
| Najat Khan | Chief Officer | Profile | |
| Christopher Gibson | CEO CoFounder | Profile | |
| Kevin Leggat | Vice Accounting | Profile | |
| Janelle Gordon | Vice Operations | Profile | |
| Shafique MD | Interim Officer | Profile | |
| Lina Nilsson | Senior Platform | Profile |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.